Recommendations for the diagnosis and radiological follow-up of pituitary neuroendocrine tumours

Asa, 2017, From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): An International Pituitary Pathology Club proposal, Endocr Relat Cancer., 24, C5, 10.1530/ERC-17-0004 Iglesias, 2017, Prevalence, clinical features, and natural history of incidental clinically non-functioning pituitary adenomas, Horm Metab Res., 49, 654, 10.1055/s-0043-115645 Tjornstrand, 2014, The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011, Eur J Endocrinol., 171, 519, 10.1530/EJE-14-0144 Asa, 1998, Tumors of the pituitary gland Asa, 2008, Practical pituitary pathology: What does the pathologist need to know?, Arch Pathol Lab Med., 132, 1231, 10.5858/2008-132-1231-PPPWDT Lloyd, 2017 Saeger, 2007, Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry, Eur J Endocrinol., 156, 203, 10.1530/eje.1.02326 Raverot, 2018, European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas, Eur J Endocrinol., 178, G1, 10.1530/EJE-17-0796 Karavitaki, 2012, Prevalence and incidence of pituitary adenomas, Ann Endocrinol (Paris)., 73, 79, 10.1016/j.ando.2012.03.039 Fernandez, 2010, Prevalence of pituitary adenomas: A community-based, cross-sectional study in Banbury (Oxfordshire, UK), Clin Endocrinol (Oxf)., 72, 377, 10.1111/j.1365-2265.2009.03667.x Dekkers, 2020, The epidemiology of aggressive pituitary tumors (and its challenges), Rev Endocr Metab Disord., 21, 209, 10.1007/s11154-020-09556-7 Osamura, 2017, Pituitary adenoma, 2017, 14 Guaraldi, 2020, A practical algorithm to predict postsurgical recurrence and progression of pituitary neuroendocrine tumours (PitNET)s, Clin Endocrinol (Oxf)., 93, 36, 10.1111/cen.14197 Villa, 2019, A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): A European Pituitary Pathology Group (EPPG) proposal, Virchows Arch., 475, 687, 10.1007/s00428-019-02655-0 Picó, 2021, Recommendations on the pathological report of pituitary tumors. A consensus of experts of the Spanish Society of Endocrinology and Nutrition and the Spanish Society of Pathology, Endocrinol Diabetes Nutr., 68, 196, 10.1016/j.endinu.2020.10.004 Drummond, 2019, Clinical and pathological aspects of silent pituitary adenomas, J Clin Endocrinol Metab., 104, 2473, 10.1210/jc.2018-00688 Mete, 2016, Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas, Mod Pathol., 29, 131, 10.1038/modpathol.2015.151 Nishioka, 2015, The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas, Endocr Pathol., 26, 349, 10.1007/s12022-015-9398-z Bonneville, 2016, Magnetic resonance imaging of pituitary tumors, Front Horm Res., 45, 97, 10.1159/000442327 Bashari, 2019, Modern imaging of pituitary adenomas, Best Pract Res Clin Endocrinol Metab., 33, 10.1016/j.beem.2019.05.002 Raverot, 2015, Biological and radiological exploration and management of non-functioning pituitary adenoma, Ann Endocrinol (Paris)., 76, 201, 10.1016/j.ando.2015.04.005 Feng, 2016, Utility of 11C-methionine and 18F-FDG PET/CT in patients with functioning pituitary adenomas, Clin Nucl Med., 41, e130, 10.1097/RLU.0000000000001085 Koulouri, 2016, Localisation of an occult thyrotropinoma with (11)C-methionine PET-CT before and after somatostatin analogue therapy, Lancet Diabetes Endocrinol., 4, 1050, 10.1016/S2213-8587(16)30311-4 Koulouri, 2015, A role for 11C-methionine PET imaging in ACTH-dependent Cushing’s syndrome, Eur J Endocrinol., 173, M107, 10.1530/EJE-15-0616 Tang, 2006, 11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas, Eur J Nucl Med Mol Imaging., 33, 169, 10.1007/s00259-005-1882-0 Nieman, 2015, Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab., 100, 2807, 10.1210/jc.2015-1818 Nieman, 2008, The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab., 93, 1526, 10.1210/jc.2008-0125 Bonelli, 2000, Adrenocorticotropic hormone–dependent Cushing’s Syndrome: Sensitivity and specificity of inferior petrosal sinus sampling, Am J Neuroradiol., 21, 690 Pinker, 2005, The value of high-field MRI (3T) in the assessment of sellar lesions, Eur J Radiol., 54, 327, 10.1016/j.ejrad.2004.08.006 Satogami, 2010, Normal pituitary stalk: high-resolution MR imaging at 3T, AJNR Am J Neuroradiol., 31, 355, 10.3174/ajnr.A1836 European Medicines Agency. EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body scans 2017. Available from: https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-prac-confirms-restrictions-use-linear-gadolinium-agents_en.pdfhttps://www.ema.europa.eu/en/news/emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans. Nachtigall, 2019, Physicians’ awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a "Pituitary Society" survey, Pituitary., 22, 37, 10.1007/s11102-018-0924-0 Bonneville, 2019, A plea for the T2W MR sequence for pituitary imaging, Pituitary., 22, 195, 10.1007/s11102-018-0928-9 Pressman, 2017, Pituitary imaging, Endocrinol Metab Clin North Am., 46, 713, 10.1016/j.ecl.2017.04.012 Cao, 2018, Primary hypothyroidism in a child leads to pituitary hyperplasia: A case report and literature review, Medicine (Baltimore)., 97, 10.1097/MD.0000000000012703 Turcu, 2013, Pituitary stalk lesions: The Mayo Clinic experience, J Clin E.ndocrinol Metab., 98, 1812, 10.1210/jc.2012-4171 Sen, 2017, Role of high-resolution dynamic contrast-enhanced MRI with golden-angle radial sparse parallel reconstruction to identify the normal pituitary gland in patients with macroadenomas, AJNR Am J Neuroradiol., 38, 1117, 10.3174/ajnr.A5244 Chuang, 2017, Different volumetric measurement methods for pituitary adenomas and their crucial clinical significance, Sci Rep., 7, 40792, 10.1038/srep40792 Ouyang, 2011, Imaging of the pituitary, Radiol Clin North Am., 49, 549, 10.1016/j.rcl.2011.02.012 Raverot, 2018, Diagnosis and clinical mamagement of aggresive pituitary tumors Garmes, 2017, Pituitary carcinoma: A case report and discussion of potential value of combined use of Ga-68 DOTATATE and F-18 FDG PET/CT scan to better choose therapy, Surg Neurol Int., 8, 162, 10.4103/sni.sni_498_16 Novruzov, 2015, The use of (68)Ga DOTATATE PET/CT for diagnostic assessment and monitoring of (177)Lu DOTATATE therapy in pituitary carcinoma, Clin Nucl Med., 40, 47, 10.1097/RLU.0000000000000589 Manara, 2011, Increased rate of intracranial saccular aneurysms in acromegaly: An mr angiography study and review of the literature, J Clin Endocrinol Metab., 96, 1292, 10.1210/jc.2010-2721 Linn, 2011, Detailed imaging of the normal anatomy and pathologic conditions of the cavernous region at 3 Tesla using a contrast-enhanced MR angiography, Neuroradiology., 53, 947, 10.1007/s00234-011-0837-3 Hardy, 1976, Transsphenoidal neurosurgery of intracranial neoplasm, Adv Neurol., 15, 261 Knosp, 1993, Pituitary adenomas with invasion of the cavernous sinus space: A magnetic resonance imaging classification compared with surgical findings, Neurosurgery., 33, 610 Micko, 2015, Invasion of the cavernous sinus space in pituitary adenomas: Endoscopic verification and its correlation with an MRI-based classification, J Neurosurg., 122, 803, 10.3171/2014.12.JNS141083 Anik, 2017, Endoscopic Transsphenoidal approach for acromegaly with remission rates in 401 patients: 2010 Consensus Criteria, World Neurosurg., 108, 278, 10.1016/j.wneu.2017.08.182 Brochier, 2010, Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: A study of 142 patients, Eur J Endocrinol., 163, 193, 10.1530/EJE-10-0255 Galm, 2018, MRI texture analysis as a predictor of tumor recurrence or progression in patients with clinically non-functioning pituitary adenomas, Eur J Endocrinol., 179, 191, 10.1530/EJE-18-0291 Black, 1997, Development and implementation of intraoperative magnetic resonance imaging and its neurosurgical applications, Neurosurgery., 41, 831, 10.1097/00006123-199710000-00013 Buchfelder, 2016, Intraoperative magnetic resonance imaging for pituitary adenomas, Front Horm Res., 45, 121, 10.1159/000442328 Yoon, 2001, Pituitary adenomas: Early postoperative MR imaging after transsphenoidal resection, AJNR Am J Neuroradiol., 22, 1097 Kiliç, 2001, Determining optimal MRI follow-up after transsphenoidal surgery for pituitary adenoma: Scan at 24 hours postsurgery provides reliable information, Acta Neurochir (Wien)., 143, 1103, 10.1007/s007010100002 Taberner Lopez, 2018, Assessment of the extent of pituitary macroadenomas resection in immediate postoperative MRI, Radiologia., 60, 64 Stofko, 2014, The value of immediate postoperative MR imaging following endoscopic endonasal pituitary surgery, Acta Neurochir (Wien)., 156, 133, 10.1007/s00701-013-1834-6 Kim, 2019, Differentiation of postoperative changes and residual tumors in dynamic contrast-enhanced sella MRI after transsphenoidal resection of pituitary adenoma, Medicine (Baltimore)., 98 Cortet-Rudelli, 2015, Post-surgical management of non-functioning pituitary adenoma, Ann Endocrinol (Paris)., 76, 228, 10.1016/j.ando.2015.04.003 Hughes, 2018, Beyond gross total and subtotal: Does volumetric resection matter in nonfunctioning pituitary macroadenomas?, World Neurosurg., 116, e733, 10.1016/j.wneu.2018.05.077 Wass, 2011, The postoperative monitoring of nonfunctioning pituitary adenomas, Nat Rev Endocrinol., 7, 431, 10.1038/nrendo.2011.54 Brada, 2008, Radiotherapy for pituitary adenomas, Endocrinol Metab Clin North Am., 37, 263, 10.1016/j.ecl.2007.10.005 Minniti, 2016, Target delineation and optimal radiosurgical dose for pituitary tumors, Radiat Oncol., 11, 135, 10.1186/s13014-016-0710-y Koulouri, 2016, Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11C-methionine PET co-registered with MRI, Eur J Endocrinol., 175, 485, 10.1530/EJE-16-0639 d’Amico, 2014, CyberKnife radiosurgery planning of a secreting pituitary adenoma performed with (6)(8)Ga DOTATATE PET and MRI, Clin Nucl Med., 39, 1043, 10.1097/RLU.0000000000000535 Taku, 2017, The use of (11)carbon methionine positron emission tomography (PET) imaging to enhance radiotherapy planning in the treatment of a giant, invasive pituitary adenoma, BJR Case Rep., 3 Wang, 2018, PET/MRI in the Diagnosis of Hormone-Producing Pituitary Microadenoma: A Prospective Pilot Study, J Nucl Med., 59, 523, 10.2967/jnumed.117.191916 Trouillas, 2013, A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up, Acta Neuropathol., 126, 123, 10.1007/s00401-013-1084-y Vasiljevic, 2016, Clinicopathological prognostic and theranostic markers in pituitary tumors, Minerva Endocrinol., 41, 377 Alhambra-Exposito, 2018, Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas, Sci Rep., 8, 6173, 10.1038/s41598-018-24260-y Cuevas-Ramos, 2015, A Structural and Functional Acromegaly Classification, The Journal of Clinical Endocrinology & Metabolism., 100, 122, 10.1210/jc.2014-2468 Puig Domingo, 2015, Treatment of acromegaly in the era of personalized and predictive medicine, Clin Endocrinol (Oxf)., 83, 3, 10.1111/cen.12731 Puig-Domingo, 2019, Precision medicine in the treatment of acromegaly, Minerva Endocrinol., 44, 169, 10.23736/S0391-1977.18.02937-1 Puig-Domingo, 2010, Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure, J Clin Endocrinol Metab., 95, 4973, 10.1210/jc.2010-0573 Wang, 2018, The Relationship Between Posterior Pituitary Bright Spot on Magnetic Resonance Imaging (MRI) and Postoperative Diabetes Insipidus for Pituitary Adenoma Patients, Med Sci Monit., 24, 6579, 10.12659/MSM.908349 Surov, 2017, Associations between apparent diffusion coefficient (ADC) and KI 67 in different tumors: a meta-analysis. Part 1: ADCmean, Oncotarget, 8, 75434, 10.18632/oncotarget.20406 Tamrazi, 2017, Apparent diffusion coefficient and pituitary macroadenomas: pre-operative assessment of tumor atypia, Pituitary., 20, 195, 10.1007/s11102-016-0759-5 Bonneville, 2016, The Pituitary Gland After Radiation Therapy, 205 Azab, 2019, Endoscopic Endonasal Excision of Large and Giant Pituitary Adenomas: Radiological and Intraoperative Correlates of the Extent of Resection, World Neurosurg., 126, e793, 10.1016/j.wneu.2019.02.151 Kopp, 2012, Tumor shrinkage assessed by volumetric MRI in long-term follow-up after fractionated stereotactic radiotherapy of nonfunctioning pituitary adenoma, Int J Radiat Oncol Biol Phys., 82, 1262, 10.1016/j.ijrobp.2011.02.053 Hagiwara, 2003, Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation, Radiology., 228, 533, 10.1148/radiol.2282020695 Heck, 2012, Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly, Clin Endocrinol (Oxf)., 77, 72, 10.1111/j.1365-2265.2011.04286.x Heck, 2016, Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly, Endocrine., 52, 333, 10.1007/s12020-015-0766-8 Heck, 2016, MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly, Endocrine., 53, 327, 10.1007/s12020-015-0816-2 Potorac, 2016, T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly, Endocr Relat Cancer., 23, 871, 10.1530/ERC-16-0356 Ezzat, 2019, Predictive Markers for Postsurgical Medical Management of Acromegaly: A Systematic Review and Consensus Treatment Guideline, Endocr Pract., 25, 379, 10.4158/EP-2018-0500 Burlacu, 2019, T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists, Endocrine., 63, 323, 10.1007/s12020-018-1765-3 Kreutz, 2015, Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference, Neuroradiology., 57, 679, 10.1007/s00234-015-1519-3 Levine, 2013, Occurrence of extensive spherical amyloid deposits in a prolactin-secreting pituitary macroadenoma: a radiologic-pathologic correlation, Ann Diagn Pathol., 17, 361, 10.1016/j.anndiagpath.2013.03.001 Varlamov, 2020, Magnetic resonance imaging in the management of prolactinomas; a review of the evidence, Pituitary., 23, 16, 10.1007/s11102-019-01001-6 Dogansen, 2018, Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas, Pituitary., 21, 347, 10.1007/s11102-018-0877-3 Biagetti, 2021, Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline, Eur J Endocrinol., 185, 587, 10.1530/EJE-21-0561 Kurosaki, 2015, Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas, Neurol Res., 37, 341, 10.1179/1743132814Y.0000000457 Faje, 2016, Klibanski A. Dopamine Agonists Can Reduce Cystic Prolactinomas, The Journal of Clinical Endocrinology & Metabolism., 101, 3709, 10.1210/jc.2016-2008 Eroukhmanoff, 2017, MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment, Eur J Endocrinol., 176, 323, 10.1530/EJE-16-0897 Alkabbani, 2014, Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth?, Pituitary., 17, 97, 10.1007/s11102-013-0473-5 Rodriguez-Barcelo, 2014, Clinical usefulness of coregistered 11C-methionine positron emission tomography/3-T magnetic resonance imaging at the follow-up of acromegaly, World Neurosurg., 82, 468, 10.1016/j.wneu.2013.11.011 Serioli, 2019, Pituitary adenomas and invasiveness from anatomo-surgical, radiological, and histological perspectives: A systematic literature review, Cancers., 11, 1936, 10.3390/cancers11121936 Batista, 2005, Detection of adrenocorticotropin-secreting pituitary adenomas by magnetic resonance imaging in children and adolescents with cushing disease, J Clin Endocrinol Metab., 90, 5134, 10.1210/jc.2004-1778 Patronas, 2003, Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors, J Clin Endocrinol Metab., 88, 1565, 10.1210/jc.2002-021438 Grober, 2018, Comparison of MRI techniques for detecting microadenomas in Cushing’s disease, J Neurosurg., 128, 1051, 10.3171/2017.3.JNS163122 Chatain, 2018, Potential utility of FLAIR in MRI-negative Cushing’s disease, J Neurosurg., 129, 620, 10.3171/2017.4.JNS17234 Rogg, 2002, Pituitary apoplexy: early detection with diffusion-weighted MR imaging, AJNR Am J Neuroradiol., 23, 1240 Kunii, 2007, Rathke’s cleft cysts: Differentiation from other cystic lesions in the pituitary fossa by use of single-shot fast spin-echo diffusion-weighted MR imaging, Acta Neurochir (Wien)., 149, 759, 10.1007/s00701-007-1234-x Khant, 2019, Evaluation of pituitary structures and lesions with turbo spin-echo diffusion-weighted imaging, J Neurol Sci., 405, 10.1016/j.jns.2019.07.008 Snow, 1986, Craniotomy versus transsphenoidal excision of large pituitary tumors: the usefulness of magnetic resonance imaging in guiding the operative approach, Neurosurgery., 19, 59, 10.1227/00006123-198607000-00008 Iuchi, 1998, MRI prediction of fibrous pituitary adenomas, Acta Neurochir (Wien)., 140, 779, 10.1007/s007010050179 Yu CS, 2005, Diffusion tensor tractography in patients with cerebral tumors: A helpful technique for neurosurgical planning and postoperative assessment, Eur J Radiol., 56, 197, 10.1016/j.ejrad.2005.04.010 Salmela, 2010, Magnetic resonance diffusion tensor imaging (MRDTI) and tractography in children with septo-optic dysplasia, Pediatric Radiology., 40, 708, 10.1007/s00247-009-1478-0 Anik, 2018, Visual outcome of an endoscopic endonasal transsphenoidal approach in pituitary macroadenomas: Quantitative assessment with diffusion tensor imaging early and long-term results, World Neurosurg., 112, e691, 10.1016/j.wneu.2018.01.134 Doai, 2019, Pituitary macroadenoma: Accuracy of apparent diffusion coefficient magnetic resonance imaging in grading tumor aggressiveness, Neuroradiol J., 32, 86, 10.1177/1971400919825696 Pierallini, 2006, Pituitary macroadenomas: Preoperative evaluation of consistency with diffusion-weighted MR imaging—initial experience, Radiology., 239, 223, 10.1148/radiol.2383042204 Wang, 2018, Application of reduced-FOV diffusion-weighted imaging in evaluation of normal pituitary glands and pituitary macroadenomas, Am J Neuroradiol., 39, 1499 Yiping, 2016, Prediction of the consistency of pituitary adenoma: A comparative study on diffusion-weighted imaging and pathological results, J Neuroradiol., 43, 186, 10.1016/j.neurad.2015.09.003 Mahmoud, 2011, Role of PROPELLER diffusion-weighted imaging and apparent diffusion coefficient in the evaluation of pituitary adenomas, Eur J Radiol., 80, 412, 10.1016/j.ejrad.2010.05.023 Sanei Taheri, 2019, Accuracy of diffusion-weighted imaging-magnetic resonance in differentiating functional from non-functional pituitary macro-adenoma and classification of tumor consistency, Neuroradiol J., 32, 74, 10.1177/1971400918809825 Suzuki, 2007, Apparent diffusion coefficient of pituitary macroadenoma evaluated with line-scan diffusion-weighted imaging, J Neuroradiol., 34, 228, 10.1016/j.neurad.2007.06.007 Boxerman, 2010, Preoperative MRI evaluation of pituitary macroadenoma: Imaging features predictive of successful transsphenoidal surgery, AJR Am J Roentgenol., 195, 720, 10.2214/AJR.09.4128 Hassan, 2018, Diagnostic value of early postoperative MRI and diffusion-weighted imaging following trans-sphenoidal resection of non-functioning pituitary macroadenomas, Clin Radiol., 73, 535, 10.1016/j.crad.2017.12.007 Ma, 2016, Predictive value of PWI for blood supply and T1-spin echo MRI for consistency of pituitary adenoma, Neuroradiology., 58, 51, 10.1007/s00234-015-1591-8 Bladowska, 2013, Usefulness of perfusion weighted magnetic resonance imaging with signal-intensity curves analysis in the differential diagnosis of sellar and parasellar tumors: Preliminary report, Eur J Radiol., 82, 1292, 10.1016/j.ejrad.2013.01.033 Hakyemez, 2006, Meningiomas with conventional MRI findings resembling intraaxial tumors: Can perfusion-weighted MRI be helpful in differentiation?, Neuroradiology., 48, 695, 10.1007/s00234-006-0115-y Pinzariu, 2018, Metabolomics-A promising approach to pituitary adenomas, Front Endocrinol (Lausanne)., 9, 814, 10.3389/fendo.2018.00814 Chernov, 2009, Possible role of single-voxel 1H-MRS in differential diagnosis of suprasellar tumors, J Neurooncol., 91, 191, 10.1007/s11060-008-9698-y Einstien, 2016, Clinical relevance of single-voxel (1)H MRS metabolites in discriminating suprasellar tumors, J Clin Diagn Res., 10, TC01 Bou-Ayache, 2016, Advances in imaging of the pediatric pituitary gland, Endocrinol Metab Clin North Am., 45, 443, 10.1016/j.ecl.2016.02.004 Chapman, 2020, Neuroimaging of the pituitary gland: Practical anatomy and pathology, Radiol Clin North Am., 58, 1115, 10.1016/j.rcl.2020.07.009 Hu, 2019, Magnetic resonance spectroscopy may serve as a presurgical predictor of somatostatin analog therapy response in patients with growth hormone-secreting pituitary macroadenomas, J Endocrinol Invest., 42, 443, 10.1007/s40618-018-0939-4 Hughes, 2016, Magnetic resonance elastography detects tumoral consistency in pituitary macroadenomas, Pituitary., 19, 286, 10.1007/s11102-016-0706-5 Sakai, 2016, Shear stiffness of 4 common intracranial tumors measured using MR elastography: comparison with intraoperative consistency grading, AJNR Am J Neuroradiol., 37, 1851, 10.3174/ajnr.A4832 Lang, 2018, Comparison of constructive interference in steady-state and T1-weighted MRI sequence at detecting pituitary adenomas in Cushing’s disease patients, J Neurol Surg B Skull Base., 79, 593, 10.1055/s-0038-1642032 Yamamoto, 2014, Tumor consistency of pituitary macroadenomas: predictive analysis on the basis of imaging features with contrast-enhanced 3D FIESTA at 3T, Am J Neuroradiol., 35, 297, 10.3174/ajnr.A3667 Watanabe, 2012, Delineation of optic nerves and chiasm in close proximity to large suprasellar tumors with contrast-enhanced FIESTA MR imaging, Radiology., 264, 852, 10.1148/radiol.12111363